Overview
- Editors:
-
-
Anthony P. Sampson
-
Immunopharmacology Group, Southampton General Hospital, Southampton, UK
-
Martin K. Church
-
Immunopharmacology Group, Southampton General Hospital, Southampton, UK
Access this book
Other ways to access
Table of contents (10 chapters)
-
Front Matter
Pages i-viii
-
- James L. Lordan, Ratko Djukanović
Pages 1-33
-
-
- Hermann Tenor, Christian Schudt
Pages 87-135
-
- Joanna S. Thompson Coon, Anne E. Tattersfield
Pages 137-151
-
- Guy F. Joos, Renaat A. Peleman, Romain A. Pauwels
Pages 153-167
-
- Zuzana Diamant, Anthony P. Sampson
Pages 169-197
-
- Li Cher Loh, Neil C. Barnes
Pages 199-214
-
-
- Steven J. Compton, Andrew F. Walls
Pages 229-249
-
- Paul S. Foster, Simon P. Hogan
Pages 251-272
-
Back Matter
Pages 273-276
About this book
For some years, international guidelines on the management of asthma have stressed the importance of early intervention with anti-inflammatory drugs to prevent acute asthma exacerbations and to avert chronic inflammatory damage to the airway. Introduced by a broad survey of the targets for anti-inflammatory drugs, this book proceeds to bring together the most recent research into the mechanisms and clinical benefits of presently available anti-inflammatory treatments including corticosteroids, cromones, and theophylline. For the first time, these drugs are discussed alongside the newly introduced leukotriene modifier drugs, and in the context of frontline research into anti-inflammatory drugs of the future. Leading authorities in their fields evaluate the prospects of novel anti-IgE agents and cytokine antagonists, and examine recent developments in immunosuppressant compounds, protease inhibitors, and selective phosphodiesterase inhibitors. This book is an up-to-date and authoritative survey which will be invaluable to university and pharmaceutical company researchers working on anti-asthma and anti-allergy drugs and to respiratory physicians keeping abreast of developments in their specialty.
